FindTrial
Sign In

Eloralintide

DRUG11 trials

Sponsors

Eli Lilly & Co., Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2ObesityObstructiveOsteoarthritisOverweightOverweight or ObesitySleep ApneaSleep Apnea, Obstructive

Phase 1

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
CompletedNCT06916091
Eli Lilly and CompanyObesity, Overweight
Start: 2025-04-21End: 2025-09-09Updated: 2025-11-19
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
CompletedNCT06916065
Eli Lilly and CompanyObesity, Overweight
Start: 2025-04-09End: 2026-01-19Updated: 2026-01-30

Phase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RecruitingNCT07215559
Eli Lilly and CompanyDiabetes Mellitus, Type 2, Obesity, Overweight
Start: 2025-10-16End: 2027-05-01Target: 200Updated: 2026-03-02

Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RecruitingNCT07282600
Eli Lilly and CompanyObesity, Overweight
Start: 2025-12-15End: 2028-02-01Target: 1035Updated: 2026-03-20
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
RecruitingNCT07321886
Eli Lilly and CompanyObesity, Overweight
Start: 2026-02-06End: 2030-07-01Target: 1980Updated: 2026-03-20
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RecruitingNCT07353931
Eli Lilly and CompanyOsteoarthritis, Overweight or Obesity
Start: 2026-02-09End: 2028-05-01Target: 900Updated: 2026-03-20
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
RecruitingNCT07369011
Eli Lilly and CompanyObesity, Overweight, Sleep Apnea, Obstructive
Start: 2026-02-10End: 2028-04-01Target: 800Updated: 2026-03-20
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
RecruitingNCT07392190
Eli Lilly and CompanyObesity, Overweight
Start: 2026-02-10End: 2028-07-01Target: 900Updated: 2026-03-20
J3R-MC-YDAO - A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight (ENLIGHTEN-3) Intervention-Specific Appendices (ISAs): J3R-MC-YSA1: Participants unable or unwilling to use positive airway pressure therapy J3R-MC-YSA2: Participants treated with positive airway pressure therapy
Not yet recruitingCTIS2025-523769-11-00
Eli Lilly & Co.Obesity, Obstructive, Overweight +1
Target: 85Updated: 2026-03-20
J3R-MC-YDAG - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes
Not yet recruitingCTIS2025-523657-34-00
Eli Lilly & Co.Obesity, Overweight
Target: 62Updated: 2026-03-27
J3R-MC-YDAN - A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4) J3R-MC-YOA1: Intervention-Specific Appendix 1 (ISA1) for Eloralintide in Participants with Osteoarthritis Knee Pain J3R-MC-YOA2: Intervention-Specific Appendix 2 (ISA2) for Eloralintide in Participants with Osteoarthritis Knee Pain
Not yet recruitingCTIS2025-523768-19-00
Eli Lilly & Co.Osteoarthritis, Overweight or Obesity
Target: 20Updated: 2026-04-02